Clinical trial
Phase II 5-Azacytidine Plus VPA Plus ATRA
NCT00326170 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00326170 |
|---|---|
| Title | Phase II 5-Azacytidine Plus VPA Plus ATRA |
| Official title | Phase II Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | 5-Azacytidine (5-aza), Valproic Acid, All-Trans Retinoic Acid (ATRA) |
| Enrollment | 34 |
| Start date | Jul 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | May 16, 2006 |
| Last update posted | Jun 15, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: